CXCR2 has become a therapeutic target for many inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), allergic asthma, gram-negative sepsis, IBD, lung injury, auto-immune diseases and cancer (45, 49). This evidence concerns the gene CXCR2 and chronic obstructive pulmonary disease.